Mr. Kennedy brings wealth of experience
managing high growth organizations focused on creating value for
shareholders
DUBLIN, Feb. 27,
2024 /PRNewswire/ -- Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) today announced the appointment of a new independent
director, Patrick Kennedy, to its
Board of Directors. Mr. Kennedy, Chair and Governor of the Bank of
Ireland, has been appointed to the
Jazz Board and will serve on the Audit Committee effective
March 1, 2024. Peter Gray has decided not to seek re-election
to the Jazz Board at the next Annual General Meeting, expected in
July 2024.
Mr. Kennedy's appointment reflects Jazz's ongoing focus on Board
renewal, and his financial and operating expertise will further
enhance the skill set of the Board. Following the departure of Mr.
Gray, Jazz's Board will be comprised of twelve directors, four of
whom have been appointed in the past five years. Half of Jazz's
Board seats are held by members of diverse communities: female, of
color, and/or LGBTQIA+.
"We are thrilled to welcome Patrick to the Board," said
Bruce Cozadd, chairman and CEO,
Jazz Pharmaceuticals. "His wealth of
experience leading some of Ireland's most influential and successful
organizations and well-established global track record with
dynamic, growth-oriented companies is exceptionally aligned with
Jazz's focus on creating value for shareholders. I am
confident that Patrick's expertise will complement the capabilities
of the existing Jazz Board as we aim to transform the lives of
patients and their families."
Mr. Kennedy brings over 30 years of experience to the Jazz Board
with a successful track record across a range of global businesses.
He joined the Bank of Ireland's
Board of Directors in 2010 and has served as its chair since 2018.
Mr. Kennedy was the CEO of Paddy
Power plc (now a part of Flutter Entertainment plc), a
leading Irish brand, for nine years, was previously CFO of
Greencore Group plc, and held prior roles with KPMG Corporate
Finance and McKinsey & Company. Mr. Kennedy served as a
non-executive director of Elan Corporation plc, a biotechnology
company, and of retailer ASOS plc. He is currently also the Chair
and non-executive director of CarTrawler, a world-leading B2B
technology platform for car rental and mobility solutions.
"I am impressed by the strength of Jazz's business and the
talent within the organization," said Mr. Kennedy. "I am looking
forward to the opportunity to work alongside my Board colleagues
and the Company's management to help guide the company's future
growth, and to deliver value to our shareholders and meaningful
impact for patients."
"I want to thank Peter for his outstanding service and
dedication to Jazz," Mr. Cozadd added. "Peter has been instrumental
in the transformation of Jazz and has been a valued Board
colleague. We are grateful for his commitment to ensure a strong
transition ahead of his departure later this year."
Mr. Gray has served as a member of the Jazz Board since
May 2013 and as chair of the Audit
Committee since April 2014. For
nearly nine years, Mr. Gray served as CEO of ICON plc, a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, and as chair of the
Board of Directors of UDG Healthcare for eight years.
About Jazz Pharmaceuticals
Jazz
Pharmaceuticals plc (Nasdaq: JAZZ) is a global
biopharmaceutical company whose purpose is to innovate to transform
the lives of patients and their families. We are dedicated to
developing life-changing medicines for people with serious
diseases—often with limited or no therapeutic options. We have a
diverse portfolio of marketed medicines, including leading
therapies for sleep disorders and epilepsy, and a growing portfolio
of cancer treatments. Our patient-focused and science-driven
approach powers pioneering research and development advancements
across our robust pipeline of innovative therapeutics in oncology
and neuroscience. Jazz is headquartered in Dublin,
Ireland with research and development laboratories,
manufacturing facilities and employees in multiple countries
committed to serving patients worldwide. Please
visit www.jazzpharmaceuticals.com for more
information.
Contacts:
Jazz Media Contact:
Kristin Bhavnani
Head of Global Strategic Brand Engagement
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
Jazz Investor Contact:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-appoints-patrick-kennedy-to-its-board-of-directors-302071689.html
SOURCE Jazz Pharmaceuticals plc